This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzyme Developer Codexis Files For $100M IPO

NEW YORK (AP) ¿ Industrial enzyme developer Codexis Inc. plans to raise up to $100 million in an initial public offering in 2010.

The Redwood City, Calif., company has not yet set a date for the proposed IPO and did not say how many shares it would sell. Codexis said it will use the funds from the IPO to fund working capital and corporate activities, potentially including acquisitions or increasing its production capacity.

The planned IPO was disclosed in a filing made Monday with the Securities and Exchange Commission. The offering will be underwritten by Credit Suisse, Goldman Sachs, RBC Capital Markets, Pacific Crest Securities. Shares will trade on the Nasdaq Global Market under the symbol "CDXS."

Codexis develops technology that is used to create biocatalysts, or enzymes and microbes that are used to start or speed up chemical reactions. The company said its technology allows companies to use biological catalysts that can make their industrial processes faster, cleaner, and more efficient, and work in less complex conditions and with less expensive equipment.

Codexis gets most of its revenue from a research collaboration with oil and gas company Royal Dutch Shell PLC. It has also worked with drugmakers Dr. Reddy's Laboratories Ltd., Merck & Co., Pfizer Inc., and Ranbaxy Laboratories Ltd., and said its target markets are the pharmaceutical, biofuel, air, water, and chemicals industries.

The collaboration with Shell is currently set to last through November 2012. Codexis reported $50.5 million in revenue in 2008, and $58.7 million in the first nine months of 2009. It has lost $15.1 million from January to September this year.

Codexis incorporated in January 2002 as a subsidiary of biotechnology company Maxygen Inc. It became a separate company in March of that year.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MAXY $0.00 0.00%
MRK $57.10 0.00%
PFE $34.59 0.00%
AAPL $132.65 0.00%
FB $81.91 0.00%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs